Standard
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa : 3-year results of a phase 3 open-label extension study. / Zouboulis, Christos C.; Okun, Martin M.; Prens, Errol P.; Gniadecki, Robert; Foley, Peter A.; Lynde, Charles; Weisman, Jamie; Gu, Yihua; Williams, David A.; Jemec, Gregor B.e.
In:
American Academy of Dermatology. Journal, Vol. 80, No. 1, 2019, p. 60-69.e2.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Zouboulis, CC, Okun, MM, Prens, EP, Gniadecki, R, Foley, PA, Lynde, C, Weisman, J, Gu, Y, Williams, DA
& Jemec, GBE 2019, '
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study',
American Academy of Dermatology. Journal, vol. 80, no. 1, pp. 60-69.e2.
https://doi.org/10.1016/j.jaad.2018.05.040APA
Zouboulis, C. C., Okun, M. M., Prens, E. P., Gniadecki, R., Foley, P. A., Lynde, C., Weisman, J., Gu, Y., Williams, D. A.
, & Jemec, G. B. E. (2019).
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
American Academy of Dermatology. Journal,
80(1), 60-69.e2.
https://doi.org/10.1016/j.jaad.2018.05.040Vancouver
Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C et al.
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
American Academy of Dermatology. Journal. 2019;80(1):60-69.e2.
https://doi.org/10.1016/j.jaad.2018.05.040Author
Zouboulis, Christos C. ; Okun, Martin M. ; Prens, Errol P. ; Gniadecki, Robert ; Foley, Peter A. ; Lynde, Charles ; Weisman, Jamie ; Gu, Yihua ; Williams, David A. ; Jemec, Gregor B.e. / Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa : 3-year results of a phase 3 open-label extension study. In: American Academy of Dermatology. Journal. 2019 ; Vol. 80, No. 1. pp. 60-69.e2.
Bibtex
@article{3a3bec5a058443f8b4fe4aaef4a6e2a5,
title = "Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study",
author = "Zouboulis, {Christos C.} and Okun, {Martin M.} and Prens, {Errol P.} and Robert Gniadecki and Foley, {Peter A.} and Charles Lynde and Jamie Weisman and Yihua Gu and Williams, {David A.} and Jemec, {Gregor B.e.}",
year = "2019",
doi = "10.1016/j.jaad.2018.05.040",
language = "English",
volume = "80",
pages = "60--69.e2",
journal = "American Academy of Dermatology. Journal",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "1",
}
RIS
TY - JOUR
T1 - Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa
T2 - 3-year results of a phase 3 open-label extension study
AU - Zouboulis, Christos C.
AU - Okun, Martin M.
AU - Prens, Errol P.
AU - Gniadecki, Robert
AU - Foley, Peter A.
AU - Lynde, Charles
AU - Weisman, Jamie
AU - Gu, Yihua
AU - Williams, David A.
AU - Jemec, Gregor B.e.
PY - 2019
Y1 - 2019
U2 - 10.1016/j.jaad.2018.05.040
DO - 10.1016/j.jaad.2018.05.040
M3 - Journal article
C2 - 29860040
VL - 80
SP - 60-69.e2
JO - American Academy of Dermatology. Journal
JF - American Academy of Dermatology. Journal
SN - 0190-9622
IS - 1
ER -
